Skanska USA Commercial Development Inc. has secured another lease at 150 Second St. in Kendall Sq. with bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. bluebird bio will occupy 43,586 s/f beginning in January 2014.
"We are excited to welcome another innovative company to our building that represents the pioneering culture and personality unique to Kendall Square," said Shawn Hurley, executive vice president for Skanska in Boston. "The neighborhood continues to flourish and attract leading edge companies, like bluebird bio."
bluebird bio joins anchor tenant Foundation Medicine Inc. at 150 Second St. Foundation Medicine is a molecular information company that uses genomic analysis to help doctors identify targeted cancer treatments that might be best for each patient. Foundation Medicine Inc. is scheduled to start a 61,591 s/f lease this September which, with bluebird bio, brings the building to 85% leased.
Jones Lang LaSalle represented Skanska and Colliers International represented bluebird bio.
150 Second Street, which was completed in December 2012, is a LEED Gold pre-certified lab and office building representing Skanska's first commercial development investment in Cambridge. Skanska acquired the property in November of 2010 and self-financed the development costs for the three-story class A project.